Acrivon Therapeutics Inc’s recent filing unveils that its President and CEO Blume-Jensen Peter acquired Company’s shares for reported $82124.0 on Jan 14 ’26. In the deal valued at $1.68 per share,49,000 shares were bought. As a result of this transaction, Blume-Jensen Peter now holds 2,095,771 shares worth roughly $4.11 million.
Then, Levy Adam D. bought 8,832 shares, generating $14,999 in total proceeds. Upon buying the shares at $1.70, the Chief Financial Officer now owns 20,983 shares.
Before that, Devroe Eric bought 10,000 shares. Acrivon Therapeutics Inc shares valued at $17,218 were divested by the Chief Operating Officer at a price of $1.72 per share. As a result of the transaction, Devroe Eric now holds 75,308 shares, worth roughly $0.15 million.
A number of analysts have revised their coverage, including KeyBanc Capital Markets’s analysts, who began to cover the stock in late January with a ‘”an Overweight”‘ rating. Ladenburg Thalmann also remained covering ACRV and has increased its forecast on September 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Ladenburg Thalmann revised its rating on April 29, 2024. It rated ACRV as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ACRV
On Tuesday, Acrivon Therapeutics Inc [NASDAQ:ACRV] saw its stock fall -1.01% to $1.96. Over the last five days, the stock has gained 20.25%. Acrivon Therapeutics Inc shares have fallen nearly -64.68% since the year began. Nevertheless, the stocks have fallen -18.67% over the past one year.
How much short interest is there in Acrivon Therapeutics Inc?
A steep rise in short interest was recorded in Acrivon Therapeutics Inc stocks on 2025-12-31, growing by 0.97 million shares to a total of 5.33 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 4.36 million shares. There was a rise of 18.2%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 01, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $14 price target.
